British HealthTech Startup Wanda Health Secures €2.1M Funding

The platform gathers real-time patient data from homes and community settings, alerting clinicians to those at high risk.

The funding includes €960k via EIS, a mix of debt and Convertible Loan Agreement (CLA) conversions, and a €287k loan facility. EMV Capital plc, a DeepTech and life sciences VC firm, announced the raise and counts Wanda Health among its portfolio companies.

Tom Smith, Chief Executive Officer of Wanda, said: “With new funding in place and key partnerships progressing well, we are now scaling our impact across the US. With the additional capital, we are well positioned to capitalise on the growing opportunities in the rapidly expanding digital remote monitoring market and to move closer to our mission of best-in-class intelligent virtual care.”

Founded in 2014, Wanda Health offers an intelligent platform for remote patient monitoring and virtual care, built on UCLA-developed technology. It supports post-acute care, chronic disease management, and population health through real-time physiological data monitoring, patient engagement, and analytics.

Read Also - CuspAI In Talks To Raises Over $100M To Accelerate AI-Driven Material Discovery

Wanda’s system collects data from patients at home or in community settings, alerting clinicians to high-risk individuals to reduce hospitalisations and readmissions. Its multi-channel engagement tools also boost treatment adherence, helping improve patient outcomes.

“Once fully onboarded, our existing contracts are projected to provide over $3.5 million ARR, at which point we will target a Series A investment round. At that time, we expect our business to have a significantly higher valuation.

“We are incredibly grateful to EMV Capital for their continued belief in Wanda’s mission. As a long-standing partner, their trust, insight, and support have been instrumental in helping us reach our next stage of growth. Closing this round with their backing reinforces our shared vision of transforming how people engage with their health. We are excited for what lies ahead – and proud to have EMV Capital with us on the journey,” added Smith.

Earlier this year, Wanda Health partnered with the COPD Foundation and the American Heart Association, deepening its ties with key clinical opinion leaders in its focus areas.

The company also secured a major contract with Sav-Rx, a US-based PBM with a network of over 65,000 pharmacies. The deal has the potential to generate multi-million euro ARR, with onboarding already underway.

Wanda’s Provider Business continues to grow, with four new sites launching Medicare RTM, RPM, and CMM programs in areas such as sleep apnoea, pain, and chronic disease management.

Additionally, Wanda has begun working with a group of assisted living facilities in California—a new use case—with an expected recurring revenue of €259k by the end of 2025.

Dr Ilian Iliev, Chairman of Wanda and CEO of EMV Capital plc commented: “We are delighted to support Wanda as it continues to develop and build out its platform, customer base, market strategy, and leadership team. With growing demand and a clearly defined regulatory pathway, the company is continuing well on its growth journey. We look forward to seeing Wanda’s impact grow, as it scales its operations across the US, and beyond.”

About Wanda Health

Founded in 2014, Wanda Health offers a smart RPM and Virtual Care platform that improves outcomes, lowers care costs, and boosts patient and staff wellbeing. Its predictive features detect health risks up to seven days early, enabling timely clinical intervention and empowering patients to manage acute and chronic conditions.